UPDATE Friday, Jan. 28, 2022, 3:25 p.m.—The U.S. Health Resources and Services Administration (HRSA) said this afternoon it is reviewing Pfizer’s policy and will evaluate next steps as needed.
Pfizer today became the 13th drug manufacturer to impose conditions on 340B sales of prescription drugs involving contract pharmacies. Its changes take effect March 1 and affect hospitals only.
Pfizer today became the 13th drug manufacturer to impose conditions on 340B sales of prescription drugs involving contract pharmacy.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
